gastric dysmotility and cisapride
Last reviewed 01/2018
Disordered gastric motility e.g. secondary to diabetes or systemic sclerosis, was previoiusly treated with cisapride 10mg tds or qds PO. Six weeks treatment was recommended.
This drug was withdrawn from marketing in the UK from 28th July 2000 until further notice. This is because cisapride can prolong the QT interval, which may lead to rare but life-threatening ventricular arrythmias. The committee on Safety of Medicines has advised that all treatment with cisapride should be stopped and patients should be changed to an alternative treatment as necessary.
Reference:
- 1) Committee on Safety of Medicines (July 2000).Suspension of cisapride (Prepulsid): Product withdrawal.